company background image
CRBU logo

Caribou Biosciences NasdaqGS:CRBU Stock Report

Last Price

US$1.88

Market Cap

US$153.5m

7D

17.5%

1Y

-76.9%

Updated

11 Jul, 2024

Data

Company Financials +

Caribou Biosciences, Inc.

NasdaqGS:CRBU Stock Report

Market Cap: US$153.5m

CRBU Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally.

CRBU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Caribou Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Caribou Biosciences
Historical stock prices
Current Share PriceUS$1.88
52 Week HighUS$8.39
52 Week LowUS$1.50
Beta2.28
11 Month Change-3.09%
3 Month Change-55.24%
1 Year Change-76.90%
33 Year Changen/a
5 Year Changen/a
Change since IPO-88.48%

Recent News & Updates

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05
Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Recent updates

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05
Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17
More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10
Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18
Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24
Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16
Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13
Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Caribou Biosciences: Selling Close To Cash Balance

Apr 26

We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate

Oct 26
We're Not Very Worried About Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Rate

Caribou Biosciences: Another Gene Editor Hurt By The Allogene Hold

Oct 12

Shareholder Returns

CRBUUS BiotechsUS Market
7D17.5%6.0%1.0%
1Y-76.9%13.5%21.7%

Return vs Industry: CRBU underperformed the US Biotechs industry which returned 11% over the past year.

Return vs Market: CRBU underperformed the US Market which returned 22.8% over the past year.

Price Volatility

Is CRBU's price volatile compared to industry and market?
CRBU volatility
CRBU Average Weekly Movement10.9%
Biotechs Industry Average Movement10.5%
Market Average Movement5.8%
10% most volatile stocks in US Market14.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: CRBU's share price has been volatile over the past 3 months.

Volatility Over Time: CRBU's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011158Rachel Haurwitzcariboubio.com

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.

Caribou Biosciences, Inc. Fundamentals Summary

How do Caribou Biosciences's earnings and revenue compare to its market cap?
CRBU fundamental statistics
Market capUS$153.54m
Earnings (TTM)-US$115.26m
Revenue (TTM)US$33.40m

5.1x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRBU income statement (TTM)
RevenueUS$33.40m
Cost of RevenueUS$120.15m
Gross Profit-US$86.75m
Other ExpensesUS$28.51m
Earnings-US$115.26m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.28
Gross Margin-259.70%
Net Profit Margin-345.05%
Debt/Equity Ratio0%

How did CRBU perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.